NDA 021187 · Organon USA Organon
Nuvaring
Ethinyl Estradiol, Etonogestrel · Vaginal · Progestin; Estrogen
NovelLast checked: Nov 20, 2026Latest source record: May 31, 2024 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2001
Oct 3, 2001
Approved uses
4
Original approval plus efficacy supplements
Registered trials
501
113 Phase 3, 20 recruiting
FAERS reports
21,475
10,461 serious, 280 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
Boxed warning
WARNING: CIGARETTE SMOKING AND SERIOUS CARDIOVASCULAR EVENTS Cigarette smoking increases the risk of serious cardiovascular events from combination hormonal contraceptive (CHC) use. This risk increases with age, particularly in women over 35 years of age, and with the number of cigarettes smoked. For this reason, CHCs, including NuvaRing, should not be used by women who are over 35 years of age and smoke. [See Contraindications (4) .] WARNING: CIGARETTE SMOKING AND SERIOUS CARDIOVASCULAR EVENTS See full prescribing information for complete boxed warning. Women over 35 years old who smoke should not use NuvaRing. ( 4 ) Cigarette smoking increases the risk of serious cardiovascular events from combination hormonal contraceptive (CHC) use. ( 4 )
What it is approved for
From the label in effect Nov 14, 2025.
FOR VAGINAL USE ONLY NuvaRing ® is indicated for use by females of reproductive age to prevent pregnancy. NuvaRing is an estrogen/progestin combination hormonal contraceptive (CHC) indicated for use by women to prevent pregnancy. ( 1 )
Mechanism: Combination hormonal contraceptives act by suppression of gonadotropins. Although the primary effect of this action is inhibition of ovulation, other alterations include changes in the cervical mucus (which increase the difficulty of sperm entry into the uterus) and the endometrium (which reduce the likelihood of implantation).
Therapeutic areas: Endocrinology and women's health
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Sep 30, 2016 Supplement 27 · Efficacy LetterLabel
- Oct 4, 2013 Supplement 21 · Efficacy ReviewSummary ReviewLetter
- Jul 29, 2005 Supplement 12 · Efficacy LabelLetter
- Oct 3, 2001 Original approval · Type 1 - New Molecular Entity NovelReviewLetterLabel
1 products under this application
- NUVARING · ETHINYL ESTRADIOL 0.015MG/24HR; ETONOGESTREL 0.12MG/24HR · RING, VAGINAL · Prescription · TE AB
Clinical trials
Interventional ClinicalTrials.gov studies with "Ethinyl Estradiol" as an intervention, any sponsor and status, largest first.
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)NIH
NCT00006324 · 6,360 participants · Start Dec 1999
Drug: Ethinyl estradiol/levonorgestrel; Medroxyprogesterone acetate · For: HIV Infections
Sites: Research Triangle Park, North Carolina
- A Study to Evaluate the Efficacy and Safety of DR-103 for the Prevention of PregnancyPivotal-lookingCompleted
Teva Women's HealthTeva (TEVA)
NCT00996580 · 3,597 participants · Start Oct 2009 · Primary completion Sep 2011
Drug: DR-103 · For: Pregnancy Prevention
Sites: Montgomery, Alabama; Phoenix, Arizona; Tucson, Arizona · 94 sites in all
- Study of the Contraceptive Efficacy and Safety of a NOMAC-E2 Combined Oral Contraceptive (COC)(P06448)Pivotal-lookingTerminated
Organon and CoIndustry
NCT01656434 · 3,173 participants · Start Nov 2, 2012 · Primary completion Feb 12, 2014
Drug: NOMAC-E2; NETA-EE and 2 more · For: Contraception
- A Study to Evaluate the Efficacy and Safety of DR-102 for the Prevention of PregnancyPivotal-lookingCompleted
Teva Branded Pharmaceutical Products R&D, Inc.Teva (TEVA)
NCT01178125 · 2,858 participants · Start Aug 2010 · Primary completion Jan 2013
Drug: DR-102 · For: Contraception; Female Contraception
Sites: Montgomery, Alabama; Phoenix, Arizona; Little Rock, Arkansas · 62 sites in all
- Efficacy and Safety Study of the Combined Oral Contraceptive NOMAC-E2 Compared to a COC Containing DRSP/EE (292002)(P05722)Pivotal-lookingCompleted
Organon and CoIndustry
NCT00413062 · 2,281 participants · Start Jun 2006 · Primary completion Aug 2008
Drug: NOMAC-E2; DRSP-EE · For: Contraception
- Open-label Study to Evaluate the Efficacy and Safety of an Extended-cycle, Low Dose Combination Oral ContraceptivePivotal-lookingCompleted
Duramed ResearchIndustry
NCT00196326 · 2,235 participants · Start Jun 2005 · Primary completion Jun 2007
Drug: DR-1011 · For: Contraception
Sites: Huntsville, Alabama; Phoenix, Arizona; Tucson, Arizona · 55 sites in all
- Efficacy and Safety of the Combined Oral Contraceptive (COC) NOMAC-E2 Compared to a COC Containing DRSP/EE (292001)(COMPLETED)(P05724)Pivotal-lookingCompleted
Organon and CoIndustry
NCT00511199 · 2,152 participants · Start May 1, 2006 · Primary completion Apr 1, 2008
Drug: NOMAC-E2; DRSP-EE · For: Contraception
- Efficacy, Safety and Tolerability Study of Agile AG200-15 Transdermal Contraceptive Delivery SystemPivotal-lookingCompleted
Agile TherapeuticsIndustry
NCT02158572 · 2,032 participants · Start Aug 2014 · Primary completion Nov 2016
Drug: AG200-15 · For: Healthy
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- pulmonary embolism3,951
- deep vein thrombosis2,659
- inappropriate schedule of drug administration2,229
- device expulsion1,366
- no adverse event1,204
- headache1,151
- metrorrhagia1,132
- incorrect drug administration duration1,017
- nausea1,012
- unintended pregnancy956
- depression910
- anxiety862
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2004 | 1,304 |
| 2005 | 130 |
| 2006 | 255 |
| 2007 | 173 |
| 2008 | 190 |
| 2009 | 483 |
| 2010 | 678 |
| 2011 | 1,020 |
| 2012 | 1,697 |
| 2013 | 2,982 |
| 2014 | 3,782 |
| 2015 | 1,561 |
| 2016 | 1,659 |
| 2017 | 1,512 |
| 2018 | 1,184 |
| 2019 | 747 |
| 2020 | 690 |
| 2021 | 347 |
| 2022 | 315 |
| 2023 | 186 |
| 2024 | 184 |
| 2025 | 164 |
| 2026 | 232 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Nuvaring (Etonogestrel/Ethinyl Estradiol)
2024 spending
$168K
Beneficiaries
148
520 claims
Per beneficiary
$1,135
$152.65 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $0 |
| 2021 | $58,779 |
| 2022 | $233,115 |
| 2023 | $196,550 |
| 2024 | $167,917 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Effects of the selective AMPA modulator NBI-1065845 on the pharmacokinetics of midazolam or ethinyl estradiol-levonorgestrel in healthy adults.
Lin S, Ionescu A, Maynard-Scott J, et al. · Clin Transl Sci 2024 · Clinical Trial, Phase I, Research Support, Non-U.S. Gov't
- Impact of Estetrol Combined with Drospirenone on Blood Coagulation and Fibrinolysis in Patients with Endometriosis: A Multicenter, Randomized, Open-Label, Active-Controlled, Parallel-Group Study.
Kobayashi T, Hirayama M, Nogami M, et al. · Clin Appl Thromb Hemost 2024 · Randomized Controlled Trial, Multicenter Study
- The bioavailability of ethinyloestradiol and levonorgestrel in patients with an ileostomy.
Grimmer SF, Back DJ, Orme ML, et al. · Contraception 1986 · Clinical Trial, Randomized Controlled Trial
- Treatment of vaginal bleeding irregularities induced by progestin only contraceptives.
Abdel-Aleem H, d'Arcangues C, Vogelsong KM, et al. · Cochrane Database Syst Rev 2013 · Meta-Analysis, Research Support, Non-U.S. Gov't
- Treatment of vaginal bleeding irregularities induced by progestin only contraceptives.
Abdel-Aleem H, d'Arcangues C, Vogelsong KM, et al. · Cochrane Database Syst Rev 2013 · Meta-Analysis, Research Support, Non-U.S. Gov't
- Antiandrogens: clinical applications.
Sciarra F, Toscano V, Concolino G, et al. · J Steroid Biochem Mol Biol 1990 · Clinical Trial, Comparative Study
Sponsor: Merck & Co.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.